FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133949928> ?p ?o ?g. }

• W3133949928 endingPage "382" @default.
• W3133949928 startingPage "374" @default.
• W3133949928 abstract "The hypothesis of a curable oligometastatic prostate cancer (PCa) state remains to be clinically-proven. Conventional imaging often fails to localize early recurrences, hampering the potential for radical approaches.We hypothesize that prostate-specific membrane antigen (PSMA)-targeted PET-MR/CT allows for earlier detection and localization of oligorecurrent-PCa, unveiling a molecularly-defined state amenable to curative-intent metastasis-directed treatment (MDT).Single-institution single-arm phase-two study. Patients with rising PSA (0.4-3.0 ng/mL) after maximal local therapy (radical prostatectomy and post-operative radiotherapy), negative conventional staging, and no prior salvage hormonal therapy (HT) were eligible.All patients underwent [18F]DCFPyL PET-MR/CT. Patients with molecularly-defined oligorecurrent-PCa had MDT (stereotactic ablative body radiotherapy [SABR] or surgery) without HT.Primary endpoint was biochemical response (complete, i.e. biochemical 'no evidence of disease' [bNED], or partial response [100% or ≥50% PSA decline from baseline, respectively]) after MDT. Simon's two-stage design was employed (null and alternate hypotheses <5% and >20% response rate, respectively), with α and β of 0.1.Seventy-two patients were enrolled (May/2017-July/2019). Thirty-eight (53%) had PSMA-detected oligorecurrent-PCa amenable for MDT. Thirty-seven (51%) agreed to MDT: 10 and 27 underwent surgery and SABR, respectively. Median follow-up was 15.9 months (IQR 9.8-19.1). Of patients receiving MDT, the overall response rate was 60%, including 22% rendered bNED. One (2.7%) grade 3 toxicity (intra-operative ureteric injury) was observed.PSMA-defined oligorecurrent-PCa can be rendered bNED, a necessary step towards cure, in 1 of 5 patients receiving MDT alone. Randomized trials are justified to determine if MDT +/- systemic agents can expand the curative therapeutic armamentarium for PCa.We studied men treated for prostate cancer with rising PSA. We found PSMA imaging detected recurrent cancer in three-quarters of patients, and targeted treatment to these areas significantly decreased PSA in half of patients." @default.
• W3133949928 created "2021-03-15" @default.
• W3133949928 creator A5000970066 @default.
• W3133949928 creator A5001659044 @default.
• W3133949928 creator A5005156213 @default.
• W3133949928 creator A5007710281 @default.
• W3133949928 creator A5008048551 @default.
• W3133949928 creator A5012397578 @default.
• W3133949928 creator A5013192823 @default.
• W3133949928 creator A5015087698 @default.
• W3133949928 creator A5016850642 @default.
• W3133949928 creator A5018908850 @default.
• W3133949928 creator A5020292379 @default.
• W3133949928 creator A5020744487 @default.
• W3133949928 creator A5021475018 @default.
• W3133949928 creator A5022511452 @default.
• W3133949928 creator A5026175733 @default.
• W3133949928 creator A5037763217 @default.
• W3133949928 creator A5037879134 @default.
• W3133949928 creator A5050303972 @default.
• W3133949928 creator A5055948301 @default.
• W3133949928 creator A5061721154 @default.
• W3133949928 creator A5070845208 @default.
• W3133949928 creator A5081688624 @default.
• W3133949928 creator A5087189944 @default.
• W3133949928 creator A5088388062 @default.
• W3133949928 date "2021-09-01" @default.
• W3133949928 modified "2023-10-15" @default.
• W3133949928 title "Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis" @default.
• W3133949928 cites W1517749817 @default.
• W3133949928 cites W1900676315 @default.
• W3133949928 cites W1994463565 @default.
• W3133949928 cites W2016451441 @default.
• W3133949928 cites W2022099031 @default.
• W3133949928 cites W2029409133 @default.
• W3133949928 cites W2031688279 @default.
• W3133949928 cites W2158789700 @default.
• W3133949928 cites W2278701757 @default.
• W3133949928 cites W2463848034 @default.
• W3133949928 cites W2470255787 @default.
• W3133949928 cites W2511755939 @default.
• W3133949928 cites W2596956169 @default.
• W3133949928 cites W2620798309 @default.
• W3133949928 cites W2664930764 @default.
• W3133949928 cites W2761351587 @default.
• W3133949928 cites W2767249739 @default.
• W3133949928 cites W2775321189 @default.
• W3133949928 cites W2799328879 @default.
• W3133949928 cites W2805432229 @default.
• W3133949928 cites W2811260982 @default.
• W3133949928 cites W2885666779 @default.
• W3133949928 cites W2913023403 @default.
• W3133949928 cites W2924617625 @default.
• W3133949928 cites W2939770857 @default.
• W3133949928 cites W2944301866 @default.
• W3133949928 cites W2947014957 @default.
• W3133949928 cites W2963794755 @default.
• W3133949928 cites W2972533565 @default.
• W3133949928 cites W2981468397 @default.
• W3133949928 cites W3012827461 @default.
• W3133949928 cites W3013251573 @default.
• W3133949928 cites W3018861031 @default.
• W3133949928 cites W3088633614 @default.
• W3133949928 cites W4240340450 @default.
• W3133949928 doi "https://doi.org/10.1016/j.eururo.2021.02.031" @default.
• W3133949928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33685838" @default.
• W3133949928 hasPublicationYear "2021" @default.
• W3133949928 type Work @default.
• W3133949928 sameAs 3133949928 @default.
• W3133949928 citedByCount "41" @default.
• W3133949928 countsByYear W31339499282021 @default.
• W3133949928 countsByYear W31339499282022 @default.
• W3133949928 countsByYear W31339499282023 @default.
• W3133949928 crossrefType "journal-article" @default.
• W3133949928 hasAuthorship W3133949928A5000970066 @default.
• W3133949928 hasAuthorship W3133949928A5001659044 @default.
• W3133949928 hasAuthorship W3133949928A5005156213 @default.
• W3133949928 hasAuthorship W3133949928A5007710281 @default.
• W3133949928 hasAuthorship W3133949928A5008048551 @default.
• W3133949928 hasAuthorship W3133949928A5012397578 @default.
• W3133949928 hasAuthorship W3133949928A5013192823 @default.
• W3133949928 hasAuthorship W3133949928A5015087698 @default.
• W3133949928 hasAuthorship W3133949928A5016850642 @default.
• W3133949928 hasAuthorship W3133949928A5018908850 @default.
• W3133949928 hasAuthorship W3133949928A5020292379 @default.
• W3133949928 hasAuthorship W3133949928A5020744487 @default.
• W3133949928 hasAuthorship W3133949928A5021475018 @default.
• W3133949928 hasAuthorship W3133949928A5022511452 @default.
• W3133949928 hasAuthorship W3133949928A5026175733 @default.
• W3133949928 hasAuthorship W3133949928A5037763217 @default.
• W3133949928 hasAuthorship W3133949928A5037879134 @default.
• W3133949928 hasAuthorship W3133949928A5050303972 @default.
• W3133949928 hasAuthorship W3133949928A5055948301 @default.
• W3133949928 hasAuthorship W3133949928A5061721154 @default.
• W3133949928 hasAuthorship W3133949928A5070845208 @default.
• W3133949928 hasAuthorship W3133949928A5081688624 @default.
• W3133949928 hasAuthorship W3133949928A5087189944 @default.
• W3133949928 hasAuthorship W3133949928A5088388062 @default.

• next